Discusses why women should report all cases of known or suspected harm from prescription drugs and medicines. Provides contact information for consumers who wish to file a report.
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement.
Presents a letter sent by the Executive Director of the Canadian Women's Health Network in response the amendment to remove levonorgestrel when used as emergency contraceptive from Schedule F (move to non-prescription status).
Works to highlight and validate consumer experiences and heighten consumer involvement in adverse drug reaction reporting. Aims to facilitate networking among individual patients/consumers and advocacy groups who share our concerns about the lack of adequate post-market monitoring by the pharmaceutical industry and Health Canada. Also aims to raise public awareness about the role of consumers/patients in reporting their own adverse drug reactions - or those experienced by their children, a spouse, a brother or sister, or a parent. Teaches people how to report an ADR, how to encourage others to report, and what role ADR reporting has played or can play to help ensure the medicine we take is right for us.
Presents the results of a survey where Canadians were asked to give their views and opinions on the effectiveness of Health Canada's methods to communicate health product safety information.
Aims to provide the media, policy-makers, non-governmental organizations and other concerned groups with an introduction to the issues surrounding the international agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and public health.
Presents the CWHN's disagreement with the recommendation from the National Drug Scheduling Advisory Committee of the National Association of Pharmacy Regulatory Authorities for Schedule II status for levonorgestrol.
